NovaMedicaInnotech - the pharmaceutical R&D center located at the Technopolis Moscow, offers a full range of services in the pharmaceutical market in the line with Russian and EAEU GMP requirements and specializes not only in development, but also in launch and production of innovative pharmaceutical products. Unique research and manufacturing equipment allows NovaMedica Innotech to meet the challenges of the modern pharmaceutical industry, such as creating combined drug products, modified molecules, and improved generics. The Center’s manufacturing capacities can produce samples for clinical trials as well as solid dosage forms on a commercial scale.
sustainable alliances and markets for successful and innovative specialty life sciences products in Russia and Eurasia – a region with acute unmet needs and fast-growing healthcare spending
pharmaceutical company created by Rusnano and Domain Associates to support the Russian Government’s strategy of fundamentally reshaping and modernizing Russian healthcare and making it fit-for-purpose for the 21st century
“innovation for health” - a unique, patient-centric specialty pharma and life sciences value proposition dedicated to driving transformational and sustainable patient health outcomes across Russia and the CIS and to creating exceptional value for payers and for the healthcare system in general – across a range of the fastest growing therapeutic areas and clinical care contexts
will be the commercialization pathway of choice for patient-centric and game-changing specialty pharma and life sciences innovators to capture the Russia/CIS growth opportunity with our full range of R&D, regulatory, market access, sales and marketing support tools designed specifically to generate outstanding results in these markets
driven by the successful execution of the Russian Government’s Pharma 2020 strategy to reinvent Russian healthcare for the 21st century by transferring innovative healthcare technologies to Russia
an in-licensing, registration and commercialization solution for its key partners in order to build success stories for premium drugs and devices in Russia/CIS to global standards of efficiency, effectiveness and transparency. We cover the entire lifecycle from needs research and access considerations for market entry right through to ongoing sales & marketing
patient-centric specialty pharma solutions to unmet Russian/CIS needs in close cooperation with payers, regulators and healthcare professionals – across the spectrum of the fastest-growing therapeutic areas and including both hospital and specialty outpatient care settings
strategies are holistic as well as patient-centric. Our remit spans specialty drugs, medical devices and services and covers the full lifecycle of diagnostics, prevention, treatment and lifetime management in each of the key Russian/CIS therapeutic growth areas we target
a top board & C-level team of globally experienced life sciences industry talent covering all key areas from R&D, CMC, regulatory, BD, portfolio management and legal through to marketing, sales and service, as well as senior executives with years of successful track records in Russia in both pharma and related industries
NovaMedicaInnotech - the pharmaceutical R&D center located at the Technopolis Moscow, offers a full range of services in the pharmaceutical market in the line with Russian and EAEU GMP requirements and specializes not only in development, but also in launch and production of innovative pharmaceutical products. Unique research and manufacturing equipment allows NovaMedica Innotech to meet the challenges of the modern pharmaceutical industry, such as creating combined drug products, modified molecules, and improved generics. The Center’s manufacturing capacities can produce samples for clinical trials as well as solid dosage forms on a commercial scale.
pharmaceutical company created by Rusnano and Domain Associates to support the Russian Government’s strategy of fundamentally reshaping and modernizing Russian healthcare and making it fit-for-purpose for the 21st century
“innovation for health” - a unique, patient-centric specialty pharma and life sciences value proposition dedicated to driving transformational and sustainable patient health outcomes across Russia and the CIS and to creating exceptional value for payers and for the healthcare system in general – across a range of the fastest growing therapeutic areas and clinical care contexts
will be the commercialization pathway of choice for patient-centric and game-changing specialty pharma and life sciences innovators to capture the Russia/CIS growth opportunity with our full range of R&D, regulatory, market access, sales and marketing support tools designed specifically to generate outstanding results in these markets
driven by the successful execution of the Russian Government’s Pharma 2020 strategy to reinvent Russian healthcare for the 21st century by transferring innovative healthcare technologies to Russia
an in-licensing, registration and commercialization solution for its key partners in order to build success stories for premium drugs and devices in Russia/CIS to global standards of efficiency, effectiveness and transparency. We cover the entire lifecycle from needs research and access considerations for market entry right through to ongoing sales & marketing
patient-centric specialty pharma solutions to unmet Russian/CIS needs in close cooperation with payers, regulators and healthcare professionals – across the spectrum of the fastest-growing therapeutic areas and including both hospital and specialty outpatient care settings
strategies are holistic as well as patient-centric. Our remit spans specialty drugs, medical devices and services and covers the full lifecycle of diagnostics, prevention, treatment and lifetime management in each of the key Russian/CIS therapeutic growth areas we target
a top board & C-level team of globally experienced life sciences industry talent covering all key areas from R&D, CMC, regulatory, BD, portfolio management and legal through to marketing, sales and service, as well as senior executives with years of successful track records in Russia in both pharma and related industries
